Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Eculizumab (Primary)
- Indications Haemolytic uraemic syndrome
- Focus Therapeutic Use
- Acronyms ECULISHU
- 25 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 25 Oct 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 02 Oct 2015 Post-hoc analysis data will be presented at the 2015 American Society of Nephrology (ASN) Annual Meeting, as per Alexion media release.